M&A Deal Summary

Calliditas Acquires Genkyotex SA

On August 13, 2020, Calliditas acquired life science company Genkyotex SA for 20M USD

Acquisition Highlights
  • This is Calliditas’ 1st transaction in the Life Science sector.
  • This is Calliditas’ largest (disclosed) transaction.
  • This is Calliditas’ 1st transaction in Switzerland.

M&A Deal Summary
Date 2020-08-13
Target Genkyotex SA
Sector Life Science
Buyer(s) Calliditas
Deal Type Add-on Acquisition
Deal Value 20M USD
Advisor(s) Stifel, Nicolaus & Co., Inc. (Financial)
McDermott Will & Emery (Legal)

Target

Genkyotex SA

Geneva, Switzerland
Genkyotex SA is a specialty pharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Genkyotex was founded in 2006 and is based in Geneva, Switzerland.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Calliditas

Stockholm, Sweden
Category Company
Founded 2004
Sector Life Science
Employees222
Revenue 1.2B SEK (2023)
DESCRIPTION

Calliditas is a specialty pharmaceutical company developing high-value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products. Calliditas was formed in 2004 and is based in Stockholm, Sweden.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Switzerland) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal